View More Recent Stories
-
Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), 'have reasons to believe that EWTX's study is not the study in question'
-
JPMorgan is out with its 2025 outlook for biotech stocks
-
Edgewise Therapeutics (EWTX) PT Raised to $50 at Truist Securities
-
Evercore ISI Starts Edgewise Therapeutics (EWTX) at Outperform
-
Edgewise Therapeutics, Inc. (EWTX) Tops Q3 EPS by 1c
-
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
-
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
-
Edgewise Therapeutics (EWTX) PT Raised to $42 at RBC Capital
-
Edgewise Therapeutics (EWTX) PT Raised to $42 at Leerink Partners
-
Edgewise Therapeutics (EWTX) PT Raised to $33 at Truist Securities
-
Edgewise Therapeutics (EWTX) Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy
-
After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics
-
Edgewise Therapeutics (EWTX) to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy
-
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
-
Edgewise Therapeutics, Inc. (EWTX) Tops Q2 EPS by 1c
-
RBC's biotech survey shows investors more bearish vs. last time
-
2Q24 U.S. biotech earnings preview
-
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
-
Edgewise Therapeutics Inc. (EWTX) Added to Wedbush Best Ideas List

